Landscape Capital Management L.L.C. Has $575,000 Stock Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Landscape Capital Management L.L.C. raised its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 10.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,554 shares of the medical device company’s stock after purchasing an additional 1,313 shares during the quarter. Landscape Capital Management L.L.C.’s holdings in Tandem Diabetes Care were worth $575,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Sei Investments Co. grew its stake in shares of Tandem Diabetes Care by 125.8% in the 1st quarter. Sei Investments Co. now owns 17,349 shares of the medical device company’s stock valued at $614,000 after buying an additional 9,666 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Tandem Diabetes Care by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 7,052,570 shares of the medical device company’s stock worth $249,732,000 after purchasing an additional 30,664 shares during the last quarter. BOKF NA raised its holdings in shares of Tandem Diabetes Care by 28.9% during the 1st quarter. BOKF NA now owns 23,817 shares of the medical device company’s stock valued at $806,000 after purchasing an additional 5,345 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Tandem Diabetes Care by 5.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 38,732 shares of the medical device company’s stock valued at $1,372,000 after purchasing an additional 1,985 shares during the last quarter. Finally, Silvercrest Asset Management Group LLC increased its position in Tandem Diabetes Care by 4.3% during the first quarter. Silvercrest Asset Management Group LLC now owns 266,158 shares of the medical device company’s stock worth $9,425,000 after buying an additional 10,907 shares during the last quarter.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Royal Bank of Canada began coverage on Tandem Diabetes Care in a research report on Wednesday, October 2nd. They issued an “outperform” rating and a $65.00 price target for the company. Wells Fargo & Company boosted their target price on Tandem Diabetes Care from $50.00 to $55.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. UBS Group upgraded Tandem Diabetes Care to a “hold” rating in a report on Friday, August 2nd. Sanford C. Bernstein began coverage on shares of Tandem Diabetes Care in a research note on Wednesday, November 6th. They issued an “outperform” rating and a $42.00 price objective for the company. Finally, Piper Sandler reiterated an “overweight” rating and issued a $55.00 target price (up from $50.00) on shares of Tandem Diabetes Care in a research note on Friday, August 2nd. Five investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $54.25.

Insider Activity at Tandem Diabetes Care

In other Tandem Diabetes Care news, Director Kim D. Blickenstaff sold 10,000 shares of the company’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $30.00, for a total value of $300,000.00. Following the sale, the director now directly owns 195,190 shares in the company, valued at $5,855,700. This represents a 4.87 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 2.20% of the stock is currently owned by insiders.

Tandem Diabetes Care Price Performance

Shares of NASDAQ:TNDM opened at $30.81 on Friday. The firm has a market capitalization of $2.02 billion, a PE ratio of -15.96 and a beta of 1.36. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. Tandem Diabetes Care, Inc. has a 1-year low of $18.45 and a 1-year high of $53.69. The business’s 50 day moving average is $36.16 and its 200-day moving average is $41.26.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings results on Wednesday, November 6th. The medical device company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.08. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The firm had revenue of $243.97 million for the quarter, compared to the consensus estimate of $224.14 million. During the same quarter in the previous year, the company earned ($0.38) earnings per share. The business’s revenue was up 31.4% compared to the same quarter last year. Sell-side analysts predict that Tandem Diabetes Care, Inc. will post -1.73 earnings per share for the current year.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.